• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Phathom

Then how about you go sell your oncology & rare disease products and hop off this thread? These are peoples lives/jobs at stake. Age is irrelevant. We’ve all been through a rigorous interview process. Why are you on here ?

It’s sobering to see a bunch of people getting so wound up about a reflux drug. The current job market must be incredibly tight or folks here are the bottom of the talent barrel
 
















This place is a sinking ship. Too bad because my manager is solid. Typical small company, regulatory and CMC is a mess. Head of regulatory hosted a town hall 2 weeks ago to reassure everyone. Now we got two crls. Hopefully he’s the first to go, but I’m sure it will be us.
 








































Manager said that I’d likely get an updated offer in September and that I should plan for a start in November, but that could change. My sense is they still haven’t figured it out yet. Read the press release and there were lots of caveats, “potential approval”. I’m not holding my breath.
 




Seeing how Phathom somehow screwed up what should have been a relatively simple launch- Why is Pharma in general so prone to having incompetent c suite management?
Because they went diverse. As you are seeing in every economic sector, diverse doesn't equal the best. We are seeing the collapse of everything in the name of diverse.